VAERS Explorer
Back to explore

Report #2827648

Received Feb 22, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
52 yrs
State
CA
Recovered
Recovered
Vaccinated
Feb 21, 2025
Onset
Feb 1, 2025
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
RSVRSV (ABRYSVO)PFIZER\WYETH2HY1813IM / LA

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

The resident was given 2 doses of RSV vaccine . One on R deltoid and another one on L deltoid at same day.

Current illness

None

Medical history

Anemia (Chronic) Unknown Spinal cord injury at T1-T6 level (HCC) (Chronic) 6/5/2022 Neurogenic bladder (Chronic) 6/6/2022 Neurogenic bowel (Chronic) 6/6/2022 AKI (acute kidney injury) (HCC) 6/6/2022 TBI (traumatic brain injury) (HCC) (Chronic) 6/6/2022 Hypotension (Chronic) 6/13/2022 Pressure injury of sacral region, stage 1 (Chronic) 8/22/2022 Pressure injury of left knee, stage 1 (Chronic) 8/22/2022 Pressure injury of right heel, stage 1 (Chronic) 8/22/2022 Pressure injury of left heel, stage 1 (Chronic) 8/22/2022 Constipation (Chronic) Unknown Pseudoaneurysm of carotid artery (HCC) (Chronic) 10/8/2022 S/P fusion of thoracic spine (Chronic) 11/23/2022 Closed fracture of cervical vertebra (HCC) 11/23/2022 Pain Unknown Sepsis with acute renal failure and septic shock (HCC) 4/26/2023 Paraplegia (HCC) (Chronic)

Other medications

ascorbic acid, aspirin chewable tablet 81 mg, cholecalciferol (VITAMIN D3) tablet 2,000 Units , cranberry fruit tablet 450 mg ,docusate sodium (COLACE) tablet 200 mg ,escitalopram oxalate (LEXAPRO) tablet 10 mg ,midodrine , (PROAMATINE) tab

Allergies

No known Allergies

Lab data

None. The patient is stable . No adverse effect noted. No complain of pain in the injection site. Vitals stable. No fever. No redness in the injection site.